Canay YILMAZ ASAN, Zeynep Burçin GÖNEN, Emine Fulya AKKOYUN, Alper ALKAN, Erdem KILINÇ

MRONJ Maksiller Sinüs Kalınlığını ve Sinüs Volümünü Etkiler mi?

Amaç: Bifosfonatlar (BPs), antirezorptif etkilerinden dolayı sıklıkla tercih edilen ilaçlardır. Çenelerin ilaçlarla ilişkili osteonekrozu (MRONJ), BP'lerin bir komplikasyonudur. Bu çalışmanın amacı, MRONJ hastalarının maksiller sinüs volümleri ve mukozal kalınlıklarının, sağlıklı bireylerle karşılaştırılmasıdır. Gereç ve Yöntemler: Bu çalışmada, 27 hastadaki 54 maksiller sinüse ait konik ışınlı bilgisayarlı tomografi görüntüleri değerlendirildi. Çalışmaya dahil edilen hastalar üç gruba ayrıldı. Çalışma grubu olarak belirlenen grup 1 (n=8) maksillada MRONJ gelişen hastalardan; grup 2 (n=9) BP kullanan ancak maksillada MRONJ gelişmeyen hastalardan oluşurken; kontrol grubu olan grup 3 (n=10) sağlıklı bireylerden oluşmakta idi. Gruplar arasındaki sinüs volümleri ve mukoza kalınlaşmaları istatistiksel olarak karşılaştırıldı.

Does Medication-related Osteonecrosis of the Jaw Affect Maxillary Sinus Volume and Mucosal Thickness?

Objective: Bisphosphonates (BPs) are commonly prescribed drugs because of their antiresorptive effects. However, BPs may cause medication-related osteonecrosis of the jaw (MRONJ). This study aimed to compare the maxillary sinus volumes and mucosal thickening of patients with MRONJ and healthy patients.Materials and Methods: This retrospective cohort study evaluated cone-beam computed tomography images of 54 maxillary sinuses in 27 patients. Patients were divided into three groups: group 1 (n=8), patients with maxillary MRONJ; group 2 (n=9), patients treated with BPs and had no maxillary osteonecrosis (study groups); and group 3 (n=10), healthy individuals (control group). Maxillary sinus volumes and mucosal thickening were compared among the groups.Results: No statistically significant difference in maxillary sinus volumes was found among the groups (p=0.153). The mean mucosal thickening was 5.920±5.94 mm in group 1, 1.718±2.58 in group 2 and 1.265±0.83 in group 3. Mucosal thickening was prominent significantly in Group 1 (p=0.001). Conclusion: BPs can affect oral soft tissues as well as hard tissues. The study results showed significant changes in maxillary sinus mucosal thickening in patients with maxillary MRONJ.

PDF

___

1. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67: 2-12.
2. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, Chapman R, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95: 297-304.
3. Delmas PD, Meunier PJ. The management of Paget’s disease of bone. N Engl J Med 1997; 336: 558-66.
4. Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20: 977-86.
5. Maurer P, Sandulescu T, Kriwalsky MS, Rashad A, Hollstein S, Stricker I, et al. Bisphosphonate-related osteonecrosis of the maxilla and sinusitis maxillaris. Int J Oral Maxillofac Surg 2011; 40: 285-91.
6. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-7.
7. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120-3.
8. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonateinduced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-75.
9. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-34.
10. Voss PJ, Vargas Soto G, Schmelzeisen R, Izumi K, Stricker A, Bittermann G, et al. Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla. Head Face Med 2016; 12: 3.
11. Mast G, Otto S, Mücke T, Schreyer C, Bissinger O, Kolk A, et al. Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw. J Craniomaxillofac Surg 2012; 40: 568-71.
12. Gallego L, Junquera L, Pelaz A, García-Consuegra L, AlvarezArenal A, Costilla S. Sinus mucosal thickening in bisphosphonaterelated osteonecrosis of the jaws: a case-control study. ORL J Otorhinolaryngol Relat Spec 2014; 76: 199-206.
13. Ohlrich EJ, Coates DE, Cullinan MP, Milne TJ, Zafar S, Zhao Y, et al. The bisphosphonate zoledronic acid regulates key angiogenesisrelated genes in primary human gingival fibroblasts. Arch Oral Biol 2016; 63: 7-14.
14. Lam DK, Sándor GKB, Holmes HI, Evans AW, Clokie CML. A review of bisphosphonate-associated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007; 73: 417-22.
15. Bae S, Sun S, Aghaloo T, Oh J-E, McKenna CE, Kang MK, et al. Development of oral osteomucosal tissue constructs in vitro and localization of fluorescently-labeled bisphosphonates to hard and soft tissue. Int J Mol Med 2014; 34: 559-63.
16. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005; 69: 35-43.
17. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-44.
18. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-61.
19. Arai N, Inoue S, Tomihara K, Tsuno H, Noguchi M. In vitro synergistic effects of zoledronic acid and calcium on viability of human epithelial cells. Oral Dis 2013; 19: 200-5.
20. Choi H, Lee JH, Kim HJ, Park W, Lee J-H, Kim J-H. Genetic association between VEGF polymorphisms and BRONJ in the Korean population. Oral Dis 2015; 21: 866-71.
21. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014; 72: 1938-56.
22. Olutayo J, Agbaje JO, Jacobs R, Verhaeghe V, Velde FV, Vinckier F. Bisphosphonate-Related Osteonecrosis of the Jaw Bone: Radiological Pattern and the Potential Role of CBCT in Early Diagnosis. J Oral Maxillofac Res 2010; 1: e3.
23. Wilde F, Heufelder M, Lorenz K, Liese S, Liese J, Helmrich J, et al. Prevalence of cone beam computed tomography imaging findings according to the clinical stage of bisphosphonaterelated osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 114: 804-11.
24. Thumbigere-Math V, Sabino MC, Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg 2009; 67: 1904-13.
25. Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008; 42: 848-60.